个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 自然指数

作者：
Hu Junyi[1] * ; Wang Shao-Gang[1] * ; Hou Yaxin[1] * ; Chen Zhaohui[2] * ; Liu Lilong[1] ; Li Ruizhi[3] ; Li Nisha[3,4] ; Zhou Lijie[5] ; Yang Yu[6] ; Wang Liping[7] ; Wang Liang[2] ; Yang Xiong[2] ; Lei Yichen[8] ; Deng Changqi[2] ; Li Yang[1] ; Deng Zhiyao[1] ; Ding Yuhong[1] ; Kuang Yingchun[1] ; Yao Zhipeng[1] ; Xun Yang[1] ; Li Fan[1] ; Li Heng[1] ; Hu Jia[1] ; Liu Zheng[1] ; Wang Tao[1] ; Hao Yi[9] ; Jiao Xuanmao[10] ; Guan Wei[11] ; Tao Zhen[12,13] ; Ren Shancheng[14] ; Chen Ke[15] ;
单位： [1]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China. [2]Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [3]Shanghai Luming Biotech, Shanghai, China. [4]Shanghai OE Biotech, Shanghai, China. [5]Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. [6]Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. [7]Department of Pathology, Baylor Scott & White Medical Center, Temple, TX, USA. [8]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. [9]Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [10]Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Philadelphia, PA, USA. [11]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China. [12]Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. [13]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China. [14]Department of Urology, Second Affiliated Hospital of Naval Medical University, Shanghai, China. [15]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China.
出处：
DOI： 10.1038/s41588-024-01662-5
ISSN：

摘要：
Clear cell renal cell carcinoma (ccRCC) is a complex disease with remarkable immune and metabolic heterogeneity. Here we perform genomic, transcriptomic, proteomic, metabolomic and spatial transcriptomic and metabolomic analyses on 100 patients with ccRCC from the Tongji Hospital RCC (TJ-RCC) cohort. Our analysis identifies four ccRCC subtypes including De-clear cell differentiated (DCCD)-ccRCC, a subtype with distinctive metabolic features. DCCD cancer cells are characterized by fewer lipid droplets, reduced metabolic activity, enhanced nutrient uptake capability and a high proliferation rate, leading to poor prognosis. Using single-cell and spatial trajectory analysis, we demonstrate that DCCD is a common mode of ccRCC progression. Even among stage I patients, DCCD is associated with worse outcomes and higher recurrence rate, suggesting that it cannot be cured by nephrectomy alone. Our study also suggests a treatment strategy based on subtype-specific immune cell infiltration that could guide the clinical management of ccRCC.© 2024. The Author(s).

基金：
This work was supported by grants from the Research Foundation for Talented Scholars of Tongji Hospital (2021RCYJ005), the National Natural Sciences Foundation of China (82373330 and 82073356), Beijing-Tianjin-Hebei Basic Research Cooperation Special Project (22JCZXJC00180), the Science & Technology Development Fund of Tianjin Education Commission for Higher Education (2021ZD034) and Bethune Tumor Radiotherapy Translational Medicine Research Fund (FLZH202108).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 生物学
小类 | 1 区 遗传学
最新[2025]版：
大类 | 1 区 生物学
小类 | 1 区 遗传学
JCR分区：
出版当年[2022]版：
Q1 GENETICS & HEREDITY
最新[2023]版：
Q1 GENETICS & HEREDITY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者单位： [1]Department of Urology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China.
共同第一作者：
通讯作者：
通讯机构： [12]Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. [13]Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China.
推荐引用方式(GB/T 7714)：
Hu Junyi,Wang Shao-Gang,Hou Yaxin,et al.Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression[J].Nature Genetics.2024,doi:10.1038/s41588-024-01662-5.
APA：
Hu Junyi,Wang Shao-Gang,Hou Yaxin,Chen Zhaohui,Liu Lilong...&Chen Ke.(2024).Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression.Nature Genetics,,
MLA：
Hu Junyi,et al."Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression".Nature Genetics .(2024)

资源点击量：434 今日访问量：0 总访问量：419 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）